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II instrument in relation to 6 domains proposed. Literature review of diagnosis 
criteria and when to start antiretroviral therapy according to recommended 
guidelines in people living with HIV, following search criteria in the WHO docu-
ment. RESULTS: We established methodological deficiencies in domains 3, 5 
and 6 of AGREE II in the guideline quality assessment. On Domain 3 “Rigour of 
Development” , despite the systematic literature review and quality assessment 
of the evidence reported, recommendations are based on low and very low qual-
ity information, according to GRADE. It means that the recommendations could 
have a high level of uncertainty in the estimation of long term toxicity of first line 
regimes as well as when to start therapy. In Domain 5 “Applicability” we found a 
limitation since the local context on availability of resources, the cost of products 
and other restrictions were practically ignored. States should be obliged to conduct 
this analysis before local adoption with implications of transferability and perti-
nence. Last, in Domain 6 “Editorial Independence” we found the most worrisome 
issue. The 41% of Guideline Development Group members and 25% peer review-
ers disclaimed membership of pharmaceutical industry or other advisory pan-
els, have receipt consulting fees or declared financial support through grants for 
research. Nevertheless, WHO considered this conflict of interest not relevant which 
decrease transparency and credibility of recommendations. CONCLUSIONS: 
Guidelines from WHO constituted an important global reference, however the 
way that HIV guidelines were developed showed worrisome deficiencies in qual-
ity, transparency and transferability. Since the independence of WHO is a matter 
of global controversy, countries must conduct a revision before the adoption of 
guidelines.
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OBJECTIVES: To describe the occurrence rates and causality evidence of cancer 
medication–associated adverse drug reactions (ADRs) and to evaluate Medication 
Utilization in managing the occurred ADRs. METHODS: The patient’s data was 
collected using patient data collection forms in inpatient Radiotherapy depart-
ment. The ADR assessment is done by using WHO causality assessment scale and 
Naranjo’s causality assessment scale. RESULTS: In a total of 536 patients, 78% 
(n= 418) experienced adverse drug reactions. Patients with single adverse drug 
reaction are 43% (n= 178) of 418, whereas 23% (n= 96) experienced two adverse drug 
reactions and 9% (n= 38) were found to be experiencing more than 2 adverse drug 
reactions. Alopecia 95% (n= 397), Nausea and vomiting 82% (n= 343), myelosuppres-
sion 42.1% (n= 176), Skin pigmentation 15.3% (n= 64), itching 11.4% (n= 48), Diarrhea 
11% (n= 46), mucositis 10.2% (n= 43), Constipation 6.22% (n= 26), cardiotoxicity 2% 
(n= 8) are most commonly observed ADRs. The drugs and their proportions for man-
agement of chemotherapy induced adverse drug reactions include Filgrastim (100%), 
metachlopromide (87.0%), different antibiotics like Piperacillin+Tazobactum (77.8%), 
Ceftriaxone (73.3%), Ondansetron (70%) and Dulcolax (66.6%). CONCLUSIONS: 
Approximately 78% of patients taking chemotherapy experienced adverse drug 
reactions that are mostly managed by utilizing proper medications, which further 
elucidate the opportunity for clinical pharmacists to monitor and manage adverse 
drug reactions cautiously, thereby minimizing the after effects of chemotherapy 
and improving the patient’s outcomes.
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OBJECTIVES: Active Surveillance (AS) pharmacovigilance systems better estimate 
the burden of adverse events (AEs) and generate information to allow for more 
efficient use of medicines. The objective of this activity was to implement an AS 
pilot program for first-line antiretroviral therapy (ART) medicines at 2 sentinel sites 
in Namibia. METHODS: The sentinel sites were Windhoek Central Hospital and 
Katutura Intermediate Hospital. Adults naïve to ART were enrolled, an AS Data 
Collection Form was developed and placed into the patient chart, and the doctor 
recorded ART and health information including actively recorded the presence or 
absence of AEs during each follow-up visit. We evaluated data quality by comparing 
data collected through AS forms to medical charts. We assessed incidence of AEs 
using a Cox proportional hazard model. RESULTS: A total of 413 eligible patients 
were included from August 2012 to April 2013. Demographic variables were com-
pleted on average 30% of the time and follow-up visits recorded for 82% of patients. 
Average age was 37 years; WHO Clinical Stage I for 51%; mean baseline CD4 count 
216. Most common ART regimen was TDF/3TC/NVP. The incidence of experiencing 
at least one AE was 0.3/100 person-years. Most common AE was rash followed by 
abdominal pain. After adjustment for age, gender, WHO stage, and CD4 count, those 
on TDF/3TC/EFV had 17.6 times higher risk of experiencing at least one AE (p= 0.002, 
95% CI 2.8-111.8) compared to those on TDF/3TC/NVP, and those with WHO Stage 
2 had 8.8 times higher risk (p= 0.01, 95% CI 1.9-41.2) compared to those with WHO 
Stage 1 disease. CONCLUSIONS: ART regimen and WHO stage influence the risk 
of AEs in Namibia. The quality of data collected through active surveillance in a 
resource-limited setting was high. An economic evaluation is being undertaken to 
evaluate overall feasibility of scale-up of the AS system.
Italy, and Spain, respectively. Empiric treatment with MRSA-active agents was less 
common, with teicoplanin (7.8% in Italy), clindamycin (5.9% in Spain) and van-
comycin (5.8% in Spain) among the most commonly used agents. 38.5%, 71.0%, 
48.0%, and 52.3% of patients were discharged onto continued treatment in Germany, 
UK, Italy, and Spain, respectively. Treatment switching was frequent across coun-
tries. CONCLUSIONS: Treatment of SSTIs is heterogeneous across European coun-
tries; further research is needed to understand the association between empiric 
treatment, treatment switching, and patient outcomes. This analysis, however, 
highlights the potential need for reassessment of treatment guidelines for SSTI 
and the potential need for new SSTI treatments.
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OBJECTIVES: Once-daily STRs have become an increasingly popular choice for both 
newly initiating and treatment experienced patients to improve patient adherence 
and achieve optimal outcomes. This study examines how STR prescribing trends 
have evolved in key EU countries (France, Germany, Italy, Spain and the UK) and pro-
vides insight into physician motivation to switch from conventional anti-retroviral 
(ARVs) regimen dosing to STRs. METHODS: Multi-wave retrospective medical chart 
reviews of HIV patients have been conducted in big-5-EU since 2005 to study patients 
initiating or switching ARVs during each quarter (Q) of the year. Physicians were 
recruited from a large panel to be geographically representative; they abstracted 
patient demographic, disease, and treatment data for next few consecutive HIV 
patients they encountered within a defined time period. This analysis focuses on 
STR prescribing trends between 1Q2009 and 4Q2014. RESULTS: Over 200 physicians 
abstracted 3132 and 3045 patient charts in 1Q2009 and 4Q2014 respectively. STR use 
increased in EU from 17% (France:0.5%, Germany:12%, Italy:16%, Spain:29%, UK:29%) 
in 1Q2009 to 51% in 4Q2014 (France:50%, Germany:67%, Italy:41%, Spain:51%, 
UK:46%). The top reason for switching from conventional ARV dosing to an STR 
across big-5 EU in 1Q2009 was simplification (72%), followed by tolerability (14%), 
and patient decision (12%). Importance of tolerability (19%) increased over the past 
5 years in the decision to switch, while simplification (64%) decreased; patient deci-
sion increased slightly (18%). CONCLUSIONS: STR adoption in the big-5 EU countries 
studied increased rapidly, with Germany and France having the largest increases 
from 1Q2009 to 4Q2014. There was a marked change in impetus to switch to STRs 
from simplification alone to an increasing focus on tolerability. These observed 
trends may emphasize the importance HIV providers give towards maintaining HIV 
patients on a simple and yet tolerable regimen to achieve optimal adherence and 
clinical outcomes over the longer term.
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OBJECTIVES: Acute bacterial skin and skin structure infections (ABSSSI) are among 
the most common infections treated in the hospital setting, and analysis of hos-
pital claims indicate that approximately 74% of ABSSSI hospitalizations involve 
empiric treatment with methicillin-resistant Staphylococcus aureus(MRSA)-active 
antibiotics. Many patients continue treatment post-hospital discharge; little is 
known, however, about real-world prescribing patterns. The purpose of this 
analysis was to characterize current prescribing patterns at hospital discharge 
in the United States (US). METHODS: A retrospective analysis was conducted 
using Arlington Medical Resources’ (AMR’s) Hospital Antibiotic Market audit, 
January-June 2011. The audit is comprised of data elements including patient 
demographics, diagnosis, therapy sequence, switching, and concomitance, hos-
pital and intensive care unit (ICU) length of stay (LOS), discharge drug, and drug 
costs. RESULTS: A sample of 781,331 adult hospitalized patients with ABSSSI who 
received MRSA-active IV antibiotics, projected to national volume, were included 
for analysis. Vancomycin was the most commonly prescribed MRSA-active anti-
biotic, administered to 57.07% of patients at any time during hospitalization. 
Linezolid IV (3.84%), tigecycline (2.88%), and daptomycin (1.92%) were used less 
frequently. Approximately 31% of patients were discharged with an order for 
MRSA-active IV antibiotics. Vancomycin was the most commonly prescribed IV 
antibiotic at discharge, prescribed to 24.83% of patients. Daptomycin was the next 
most commonly prescribed IV drug at discharge (3.71%). All other IV antibiotics 
were prescribed in < 1% of patients. Many patients were prescribed oral antibiot-
ics at discharge, and may have been prescribed more than one drug. Cephalexin 
(33.99%), TMP-SMZ (17.22%), clindamycin (11.08%), and linezolid (9.45%) were the 
most commonly prescribed oral antibiotics at hospital discharge. CONCLUSIONS: 
Approximately 40% of ABSSSI patients are discharged on a MRSA-active antibiotic. 
MRSA-active antibiotics that do not require multiple days of ambulatory treat-
ment following hospitalization have the potential to reduce resource utilization 
associated with continued outpatient treatment.
Pin113
conceRns on Who guidelines of tReating and PReVenting hiV 
infection
Sánchez E., Rossi F.
Fundación IFARMA, Bogotá, Colombia
OBJECTIVES: To conduct an assessment of the quality of “Consolidated guide-
lines on the use of antiretroviral drugs for treating and preventing HIV infec-
tion. Recommendations for a public health approach June 2013” by World Health 
Organization (WHO). METHODS: Quality assessment of guideline using AGREE 
